{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"285"}],"units":"Participants"}],"description":"Recommended Phase 2 dose was determined by maximum tolerated dose (MTD). MTD was defined as the next lower dose level below the one in which \\> 1 of 3 participants or ≥ 2 of 6 participants experienced dose-limiting toxicity (DLT), provided that that dose level is ≤25% lower than the highest dose tested. If the projected MTD was \\>25% lower than the highest dose tested, then an additional cohort of ≥3 participants were added at a dose that was intermediate between the intolerable dose and the next lower dose.","groups":[{"description":"Participants received selinexor doses of \\<= 12 mg/m\\^2, post oral for all cycles 3 times weekly for Weeks 1 and 3 in schedule 1; \\>12 mg/m\\^2 3 times weekly for Weeks 2 and 4 in schedule 2; \\>=30 mg/m\\^2 on Day 1 and 3 in schedule 3; \\>= 23 mg/m\\^2 on Day 1 and Day 2 for a 28-day cycle in schedule 4; \\>= 30 mg/m\\^2 on Day 1 and 4 in schedule 5; \\>= 35 mg/m\\^2 combined with dexamethasone 20 mg on Day 1 and 3 in schedule 6; \\>= 45 mg/m\\^2 once-weekly in schedule 7; \\>= 40 mg/m\\^2 twice-weekly for first 2 weeks on Days 1, 3, 8, and 10 followed by an 11-day treatment-free interval in schedule 8; \\>= 30 mg/m\\^2 twice weekly for 3 weeks in 28-day cycle followed by fixed dose of 375 mg/m\\^2 Rituximab in schedule 9; 55 mg/m\\^2 twice-weekly on Days 1, 3, 8, and 10 followed by 18-day treatment-free interval in schedule 10; 40, 60, 80 mg (group A, group B, group C) twice weekly during the first 3 weeks, on Days 1, 3, 8, 10, 15 and 17 followed by an 11-day treatment-free interval (Days 18 through 28) in schedule 11.","id":"OG000","title":"Advanced Hematological Malignancies."}],"paramType":"NUMBER","populationDescription":"Efficacy analysis set included all participants who had either completed 1 cycle of treatment or discontinued treatment prior to completing the first cycle due to documented progressive disease (PD), death related to disease, or treatment-related toxicity. Here, data was not planned and analyzed based on individual specific disease, hence overall data was analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug administration to end of treatment (up to 27 months)","title":"Recommended Phase 2 Dose (RP2D) of Selinexor","type":"PRIMARY","unitOfMeasure":"milligram per square meter (mg/m^2)"}